Literature DB >> 18826546

British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.

B G Gazzard1, Jane Anderson, Abdel Babiker, Marta Boffito, Gary Brook, Gary Brough, Duncan Churchill, Ben Cromarty, Satyajit Das, Martin Fisher, Andrew Freedman, Anna Maria Geretti, Margaret Johnson, Saye Khoo, Clifford Leen, Devaki Nair, Barry Peters, Andrew Phillips, Deenan Pillay, Anton Pozniak, John Walsh, Ed Wilkins, Ian Williams, Matthew Williams, Mike Youle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18826546     DOI： 10.1111/j.1468-1293.2008.00636.x

Source DB:  PubMed          Journal:  HIV Med        ISSN： 1464-2662            Impact factor:   3.180


× No keyword cloud information.
  121 in total

1.  CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.

Authors:  Elena López Aspiroz; Salvador Enrique Cabrera Figueroa; Alicia Iglesias Gómez; María Paz Valverde Merino; Alfonso Domínguez-Gil Hurlé
Journal:  Clin Drug Investig       Date:  2015-01       Impact factor: 2.859

Review 2.  Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.

Authors:  Maxwell O Akanbi; Kimberly K Scarsi; Kimberly Scarci; Babafemi Taiwo; Robert L Murphy
Journal:  Expert Opin Pharmacother       Date:  2012-01       Impact factor: 3.889

3.  HIV in Africa: Challenges and Directions for the Next Decade.

Authors:  Bruce L Gilliam; Devang Patel; Rohit Talwani; Zelalem Temesgen
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

4.  Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice.

Authors:  Niamh Higgins; Alice Tseng; Nancy L Sheehan; Charles J L la Porte
Journal:  Can J Hosp Pharm       Date:  2009-11

5.  Clinical utility of genotypic resistance tests for HIV-1-infected patients with low-level virological failure.

Authors:  A Elgalib; M Perry; M Aboud; J Mullen; S O'Shea; I L Chrystie; R Kulasegaram; C Y W Tong
Journal:  J Clin Microbiol       Date:  2010-07-14       Impact factor: 5.948

6.  Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.

Authors:  Chris M Parry; Madhavi Kolli; Richard E Myers; Patricia A Cane; Celia Schiffer; Deenan Pillay
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

7.  Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy.

Authors:  Alan Winston; Chris Duncombe; Patrick C K Li; John M Gill; Stephen J Kerr; Rebekah L Puls; Simon D Taylor-Robinson; Sean Emery; David A Cooper
Journal:  Neuroradiology       Date:  2012-07-07       Impact factor: 2.804

8.  Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.

Authors:  Andrew M Hill; Bonaventura Clotet; Margaret Johnson; Matthias Stoll; Nicholas Bellos; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

9.  The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France.

Authors:  Xavier Colin; Antoine Lafuma; Dominique Costagliola; Jean-Marie Lang; Pascal Guillon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

10.  Treating HIV-1 Infection: What Might the Future Hold?

Authors:  Mathias Lichterfeld; Kimon C Zachary
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.